Article Details
Retrieved on: 2021-10-24 14:46:38
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Vir Biotechnology Inc. (VIR) recently was downgraded to Sell with a D+ rating by TheStreet's Quant Ratings. This clinical stage immunology company ...
Article found on: realmoney.thestreet.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here